Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment

Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment

Immunocompromised patients are at increased risk for a severe course of COVID-19. Treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with anti-SARS-CoV-2 monoclonal antibodies (mAbs) has become widely accepted. However, the effects of mAb treatment on the long-term p...

Full description

Bibliographic Details
Main Authors: Laura Thümmler, Margarethe Konik, Monika Lindemann, Neslinur Fisenkci, Michael Koldehoff, Anja Gäckler, Peter A. Horn, Fotis Theodoropoulos, Christian Taube, Markus Zettler, Olympia Evdoxia Anastasiou, Peer Braß, Sarah Jansen, Oliver Witzke, Hana Rohn, Adalbert Krawczyk
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
COVID-19
immunosuppression
SARS-CoV-2
monoclonal antibody treatment
cellular immune response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.980698/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.980698/full

Similar Items